Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
株式のランク #13829
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
株価
$4.36
時価総額
$457.32M
変化(1日)
0.69%
変化(1年)
289.29%
US
取引 Relmada Therapeutics, Inc. (RLMD)

カテゴリー

Relmada Therapeutics, Inc.(RLMD)の配当利回りの履歴
Relmada Therapeutics, Inc.(銘柄コード: RLMD)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Relmada Therapeutics, Inc.(RLMD)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)